Objective Inhaled nitric oxide (NO) has been used for pulmonary vasodilation therapy in patients with pulmonary hypertension. Inhaled NOfor awake and ambulatory patients, however, is unusual because it requires intubation or a tightly fitting facemask, and a large-scale delivery systemfor the safe management of toxic nitrogen oxides. Weundertook this study to investigate the possibility of using inhaled NOtherapy for awake and ambulatory patients with pulmonary hypertension.
pulmonary vasodilation therapy in patients with pulmonary hypertension. Inhaled NOfor awake and ambulatory patients, however, is unusual because it requires intubation or a tightly fitting facemask, and a large-scale delivery systemfor the safe management of toxic nitrogen oxides. Weundertook this study to investigate the possibility of using inhaled NOtherapy for awake and ambulatory patients with pulmonary hypertension.
Methods Patients with pulmonary hypertension underwent cardiac catheterization and hemodynamicvariables were measured at the baseline, after inhaled NOusing our pulse delivery system, which involved a nasal cannula and a pulse device, and after inhaled NOusing a continuous delivery system.
Patients or materials Westudied seventeen patients with precapillary pulmonary hypertension (4 men and 13 women; age, 41±3, ranging from 19 to 61). Results Cardiac output was increased significantly by each system. Pulmonaryvascular resistance was decreased significantly by each system. There was no significant change in mean pulmonaryartery pressure, mean systemic artery pressure, or systemic vascular resistance. The concentrations of NOand nitrogen dioxide (NO2) in the expiratory gas using the pulse delivery system were 0.0 ppmas long as the pulse device was synchronized with the patient's respiratory cycle. Conclusion Inhaled NOusing our pulse delivery system changed the hemodynamicvariables similarly to thoseIntroduction Inhaled nitric oxide (NO) is a selective pulmonary vasodilator (1) . Its effect is considered ideal for the therapy of patients with pulmonary hypertension because, theoretically, it does not influence the systemic arterial pressure. There have been manyreports describing the use of inhaled NOin cases with various causes of pulmonary hypertension . However, the clinical application of inhaled NOis restricted to shortterm use and requires a delivery system consisting of a closed circuit with a scavenging system. Moreover, the use of inhaled NOrequires monitoring of the concentrations of inhaled and environmental NOand nitrogen dioxide (NO2) because it causes the formation of toxic NO2 (23) (24) (25) (26) . Thus, in most cases, inhaled NOhas been used for mechanically ventilated patients but has been considered difficult for awake and ambulatory patients whoneed long-term pulmonary vasodilation therapy to undergo inhaled NOtherapy. We undertook this study to investigate the possibility of using inhaled NOtherapy for awake and ambulatory patients with pulmonary hypertension. In the present study, we lowered the concentration of inhaled NOand the concentrations of NOand NO2in the expiratory gas using a pulse delivery system and compared the hemodynamiceffects of the pulse delivery system with those of a continuous delivery system.
Methods
Pa tien ts Westudied seventeen consecutive patients (4 menand 13 women; age, 41±3, ranging from 19 to 61) who underwent cardiac catheterization for diagnosis or for the estimation of therapy for precapillary pulmonary hypertension at our hospital between July 1999 and July 2000. Precapillary pulmonary hypertension wasdefined as a meanpulmonaryartery pressure over 25 mmHg and a pulmonary capillary wedgepressure below 12 mmHg. The causes of precapillary pulmonary hypertension were primary pulmonary hypertension in 8 patients, chronic pulmonary thromboembolism in 5 patients, rheumatic disease with pulmonary hypertension in 3 patients, and portopulmonary hypertension in one patient. Thepatient's characteristics are shown in Table 1 .
NOdelivery system
In the pulse delivery system (Fig. 1) , 100 ppm NOwas delivered by a nasal cannula using a pulse device (sansosaver 2, TEIJIN, Tokyo) that is generally used in home oxygen therapy for patients with chronic obstructive pulmonary disease. The onset and duration of each pulse was automatically controlled to becomeactivated during the first third of the inspiration time as predicted from the previous 3 respiratory cycles. The flow rate was fixed at 1.0 l/min. The nasal cannula had a double lumen, and the NOand oxygen were delivered separately to the end of the cannula. Expiratory gas was collected by a tightly fitting facemask and monitored for the concentrations of NO and NO2by an electrochemical analyzer (TMS-1 00, Taiyo-Toyo Sanso, Osaka). In the continuous delivery system (Fig. 2) , NOgas was delivered through a one-way inspiratory valve by a tightly fitting facemask. The concentration of inhaled NOwas regulated by changing the flow of 1,000 ppm NO, that was blended with oxygen using a mass flow controller. The concentration of inhaled NOand NO2were monitored by an electrochemical ana- Table 1 . Patient's Characteristics PPH: primary pulmonary hypertension, PTE: pulmonary thromboembolism, SJS: Sjogren's syndrome, PorPH: portopulmonary hypertension, NYHA: NewYork Heart Association functional class, BPS: beraprost sodium, CCB: calcium channel blocker, ISDN: isosorbide dinitrate, iv: intravenous administration, PGI2: epoprostenol, PGE,: alprostadil, DOA:dopamine, DOB:dobutamine, PDEIII In: phosphodiesterase III inhibitor, ACEIn: angiotensin converting enzime inhibitor, mean PAP: meanpulmonary artery pressure. In both systems, the expiratory gas was scavenged by a system consisting of a reservoir bag, soda lime, charcoal filter, and a vacuum. The concentrations of environmental NOand NO2could also be monitored as needed.
Study protocol
Oral drugs except for beraprost sodium were withheld on the morning of the catheterization. Beraprost was continued until noon. The intravenous administration of vasodilators and inotropic agents were continued during the study. Right heart catheterization was performed with a triple lumen balloontipped thermodilution catheter (Swan-Ganz thermodilution catheter, Baxter Healthcare, Irvine CA, USA). A radial or femoral artery was cannulated for measuring the systemic arterial pressure. Initially, the following hemodynamic variables were measured: pulmonary artery pressure (PAP), right atrial pressure (RAP), pulmonary capillary wedge pressure (PCWP), and systemic artery pressure (SAP). Cardiac output (CO.) was measured by the thermodilution technique. After the baseline hemodynamicvariables were measured, the patients underwent inhaled NOusing the pulse delivery system and then the continuous delivery system, each for more than 10 minutes. During the measurement of the baseline data and inhaled NOusing the pulse delivery system, patients that were already being treated with oxygen inhalation continued inhaling oxygen at the same flow rate as before the study. During inhaled NOusing the continuous delivery system, we administered 6 l/min oxygen to all patients. At the end of each inhalation, hemodynamicvariables weremeasured.Pulmonaryvascular resistance (PVR) and systemic vascular resistance (SVR) were calculated using the measured hemodynamicparameters. The concentration of inhaled NOusing the pulse delivery system was calculated using an original formula of sansosaver 2 (See the appendix for these calculation formulas). This study was approved by the Ethical Committee of the Tohoku University School of Medicine. Informed consent was obtained from all patients.
Sta tis tics
The data are expressed as the mean±SEM. Comparisons among baseline data and data for inhaled NOusing each delivery system were performed by repeated-measurement ANOVA and Bonferroni test for multiple comparisons. The concentrations of inhaled NOusing the pulse delivery system and the continuous delivery system were comparedby paired t test.
Result
The baseline hemodynamicvariables and hemodynamic effects of inhaled NOusing the pulse and continuous delivery systems are shown in Table 2 . CO. was increased significantly by each delivery system (from 3.7±0.4 //min to 4.0±0.4 with pulse and to 4.0±0.3 with continuous delivery, both p<0.05). RAP was decreased slightly but significantly by each delivery system (from 10±l mmHgto 9±1 with pulse and to 8±1 with continuous delivery, both p<0.01). PVRwas also decreased significantly by each delivery system (from 1,218±158
dyne-sec-cm-5 to l,077±136 with pulse and to l,037±120 with continuous, both p<0.01). There were no significant changes in mean PAP, mean SAP, and SVR.
During inhaled NOusing either delivery system, we could not detect NOnor NO2in the environmental air. The concentration of inhaled NOusing the pulse delivery system was significantly lower than that using the continuous delivery system haled NOusing the pulse delivery system, the concentrations of NOand NO2in the expiratory gas were 0.0 ppm as long as the pulse device was synchronized with the patient's respiratory cycle. The concentration of NOin the expiratory gas, however, transiently increased to 1.4910.3 (at the maximum4.6) ppm, but NOcould not be detected within 2 minutes and the concentration of NO2remained 0.0 ppmwhenthe patient's respiratory cycle rate rapidly varied. The methemoglobinlevels of arterial blood did not change significantly with either delivery system and did not increase over 1.2% in any patient. There were no adverse symptoms during inhaled NOusing either delivery system. Discussion
Inhaled NOusing both delivery systems decreased PVR without changing SAPsignificantly. This was the same effect as in some previous reports that studied inhaled NOfor patients with pulmonary hypertension (1, 2) . In this study, the concentration of inhaled NOusing the pulse delivery system was 25% of the concentration of inhaled NOusing the continuous delivery system. Nevertheless, the degree of hemodynamic change in inhaled NOusing the pulse delivery system was similar to that using the continuous delivery system. Previously, in a few reports attempts were madeto decrease the concentrations of inhaled NOand NO2by modifying the delivery system. showed that a synchronized inspiratory injection system reduced NO2formation in mechanically ventilated patients, but such a system was not intended for ambulatory patients (27) (28) (29) . Also, Katayamaet al reported that they succeeded in minimizing the concentration of inhaled NOusing a delivery system that injected NOat the beginning of each breath (30) . They used a tightly fitting facemask and did not examine air pollution. Their system wastherefore not for ambulatorypatients that need long-term inhaled NOtherapy. Channick et al reported a pulse delivery system consisting of a nasal cannula, pulse device that is used for homeoxygen therapy, and a tank of NOlead to a significant improvement in pulmonary hypertension with primary pulmonary hypertension (3 1). There was no measurable NOor NO2in the expiratory gas of their system. This result suggested that an NOdelivery system does not necessarily require a scavenging system. Their report also suggested that inhaled NOtherapy might be used for ambulatory patients, but they did not compare their pulse delivery system with a continuous delivery system in terms of the degree of hemodynamic changes. Ivy et al reported a comparisonof the acute hemodynamiceffects of inhaled NOusing a pulsed nasal cannula delivery with continuous mask delivery in 8 children with pulmonary hypertension (32) . The causes of pulmonary hypertension were congenital heart disease with intra-cardiac shunt in 6 patients, altitude-related pulmonary hypertension in one patient and cardiomyopathy in one patient. The present subjects were adult patients none of whomhad an intra-cardiac shunt. Our study is the only report that compares the acute hemodynamiceffects of a pulse delivery system with a nasal cannula and those of a continuous delivery system with a mask in adult patients with precapillary pulmonary hypertension. Short-term inhaled NOtherapy has been tried in cases with various types of pulmonary hypertension including persistent pulmonary hypertension of the newborn (4-7), residual pulmonaryhypertension after cardiac surgery (8-1 2), adult respiratory distress syndrome (13, 14) , Eisenmenger syndrome (15, 16) , primary pulmonary hypertension ( 1 8), pulmonary thromboembolism (19, 20) , and rheumatic disease (21, 22) . These reports demonstrated that inhaled NOis an ideal pulmonary vasodilator for patients with pulmonary hypertension. Long-term inhaled NOtherapy is, however, not commonfor patients with pulmonaryhypertension, especially awake and ambulatory patients, because of the following reasons. First, inhaled NOforms toxic NO2, which is a metabolic intermediate of NO. Second, the safety of long-term inhaled NOis unknown. Third, inhaled NOtherapy requires a large-scale system consisting of a delivery system, scavenging system and monitoring system for nitrogen oxides. Fourth, it is necessary for patients to be intubated or to wear a tightly fitting facemask to prevent leakage of nitrogen oxides to the environment. Therefore, the clinical use of inhaled NOfor awake and ambulatory patients with pulmonary hypertension is usually only for estimating pulmonary vasoreactivity by the acute response (2, 3). The present pulse delivery system included a nasal cannula to enable ambulatory patients to continue to inhale NOas comfortably as possible for a long-term period. Thus, consideration of environmental pollution was necessary because this system has an open circuit. Using the pulse device, the concentrations of NOand NO2in the expiratory gas were 0.0 ppm as long as the pulse device was synchronized with the patient's respiratory cycle. This may mean that almost all of the NOgas delivered to the alveoli at the beginning of each inspiration was diffused to the intravascular space and rapidly inactivated by binding hemoglobin. In daily life, if the patient' s respiratory rate rapidly varies in accordance with physical or mental demand, the pulse device maynot be able to control the onset and duration of each pulse properly. In such a case, a decrease of the concentration of inhaled NOand increase of the concentrations of NOand NO2in the expiratory gas mayoccur. In our study, whenthe patient's respiratory rate rapidly varied, the concentration of NOincreased to 4.6 ppm at the maximum. The increase of the concentration of NO,however, was transient and the concentration of NO2remained 0.0 ppm. Wecan regard these NOand NO2levels in the expiratory gas as within safe limits according to some safety guidelines (33, 34) . Because of the diffusion, the concentrations of NOand NO2in the environmental air would have been even lower, even if the expiratory gas had not been scavenged. This result suggested that we could use our pulse delivery system without a scavenging system, though our pulse delivery system used an open circuit. Moreover, we demonstrated that the degree of hemodynamicchange using the pulse delivery system was similar to that whenusing the continuous delivery system. Therefore, patients with pulmonary hypertension mayuse an ambulatory delivery system consisting only of a nasal cannula, a pulse device, a tank of NO, and, if necessary, a tank of O2, for longterm pulmonary vasodilation therapy without concern about environmental pollution.
Whether the hemodynamiceffect and the safety of our pulse delivery system would persist in long-term NOtherapy is unknownbecause our study was only for 10 minutes. There have been a few reports of the long-term clinical use of inhaled NO, in which inhaled NOwas continued from 8 to 12 months (17, 3 1, 35). More long-term pulmonary vasodilation therapy is needed for most patients with pulmonary hypertension. For the commonuse of long-term inhaled NOfor the patients with pulmonary hypertension, more investigation to ascertain the persistence of its safety and effect are needed.
L imita tions
We studied patients with precapillary pulmonary hypertension only in the resting supine position. For the clinical longterm use of our pulse delivery system without a scavenging system, it is unknownwhether the expiratory gas would cause problematic air pollution because it is possible that more asynchronies between the patient's respiratory rate and the pulse device could occur than in our study. Further examinations will be needed before a conclusion can be reached on the problem of air pollution. No method of measuring CO. has been considered a gold standard. Wemeasured CO. by the thermodilution technique. Patients of this study had, however, tricuspid regurgitation aris-ing from pulmonary hypertension. In the presence of tricuspid regurgitation, the values of CO. measured by the thermodilution technique maybe overestimated because tricuspid regurgitation influences the thermodilution in the right atrium and ventricle. In this study, because neither PAP nor RAPwas elevated after NOinhalation, it seems unlikely that the increase of CO. after inhalation resulted from the increase of tricuspid regurgitation.
Con clusion
The present study demonstrated that our pulse delivery system was able to induce a similar hemodynamic effect with a lower concentration of inhaled NOcompared with the continuous delivery system. Concerning possible environmental pollution, our pulse delivery system can be used safely without a scavenging system. Thus, for pulmonary vasodilation therapy of ambulatory patients with pulmonary hypertension, an ambulatory delivery system consisting of a nasal cannula, a pulse device, and a tank of NOmay be used. Further investigation, however, is necessary before long-term inhaled NOfor patients with pulmonaryhypertension can comeinto common use.
Appendix: calcuiation formula PVR(dyne-sec cnr5) and SVR(dyne sec-cnr5) were calculated using the following formula: The concentration of inhaled NO(ppm) using the pulse delivery system was calculated using the following formula: flow rate (//min)x l ,000/respiratory rate (breath/ min)/3xconcentration of supplied gas (ppm)/tidal volume (ml/ breath).
